AVIR earnings analysis
What we found in AVIR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Atea reported diluted EPS of $(0.41), an improvement versus $(0.57) in the prior quarter and $(0.44) in the prior-year quarter, while the filing does not disclose revenue, margins or free cash flow in the provided text. Liquidity was $219.5 million at June 30, 2026, against a six-month net loss of $78.4 million, $83.1 million of operating expenses and an accumulated deficit of $600.9 million. Clinical execution remains the principal catalyst, with C-FORWARD enrollment completed and topline results expected in early Q1 2027, but financing needs, China supply concentration and potential Gilead patent claims remain material risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Improved Sequentially and Year Over Year
- Diluted EPS was $(0.41), improving from $(0.57) in Q1 2026 and $(0.44) in Q2 2025 based on the reported quarterly history.
- Operating Expenses Remain Controlled
- Operating expenses were $83.1 million for the six months ended June 30, 2026, versus $180.9 million for full-year 2025, reflecting continued cost discipline.
- Losses Continue as Pipeline Advances
- The company reported a six-month net loss of $78.4 million and an accumulated deficit of $600.9 million as of June 30, 2026.
- Substantial Liquidity Remains
- Cash, cash equivalents and marketable securities totaled $219.5 million at June 30, 2026; the portfolio consisted of money-market funds, U.S. Treasuries and other short-term securities.
- C-FORWARD Enrollment Completed
- C-FORWARD enrollment was completed in June 2026, and management anticipates reporting topline results in early Q1 2027.
- HCV Intellectual Property Expanded
- A U.S. patent covering the bemnifosbuvir-and-ruzasvir HCV combination was issued on November 4, 2025, with an expected expiration in 2042; a morphic-form patent issued July 21, 2026 and expires March 31, 2043.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Cash Burn and Future Financing Needs
- Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, while the company reported a six-month net loss of $78.4 million and expects operating losses for the foreseeable future, creating a continuing financing risk.
- No Near-Term Product Revenue
- The company has no products generating commercial revenue and states that it does not anticipate product-sales revenue for at least the next few years. Six-month operating expenses were $83.1 million.
- Dependence on C-FORWARD Results
- The lead HCV program remains dependent on C-FORWARD results expected in early Q1 2027; failure of the Phase 3 trial could prevent regulatory approval and commercialization.
- Concentrated China Supply Chain
- Ruzasvir has a sole active-pharmaceutical-ingredient supplier in China, and all regulatory starting-material suppliers for ruzasvir and bemnifosbuvir are located in China, exposing supply to geopolitical, tariff and disruption risks.
- Potential Gilead Patent Conflict
- Gilead patents issued in 2023 and 2024 purport to cover bemnifosbuvir, with stated expiration dates of June 15, 2028 and March 15, 2028; an adverse court ruling could require a license or constrain commercialization.
- Prior Late-Stage Clinical Failure
- The company disclosed that the SUNRISE-3 Phase 3 COVID-19 trial failed its primary endpoint in a monotherapy cohort of 2,221 high-risk patients, leading to discontinuation of bemnifosbuvir development for COVID-19.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.41
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management anticipates reporting C-FORWARD topline results in early Q1 2027; no financial outlook was disclosed.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Avir Pharmaceuticals reported no revenue and an EPS of -$0.57 for Q1 2026, slightly missing expectations. The company is focused on advancing its clinical trials for HCV and HEV therapies, but continues to face…
- 10-K · March 5, 2026
- Atea Pharmaceuticals is a late‑stage clinical biotech focused on orally administered nucleos(t)ide antivirals: a bemnifosbuvir + ruzasvir regimen for HCV (two Phase 3 programs) and AT‑587 for HEV (preclinical → Phase 1…
- 10-Q · November 12, 2025
- Atea reported a Q3 net loss of $42,049 thousand (EPS -$0.53), larger than the prior-year quarter net loss of $31,151 thousand (EPS -$0.37). R&D spend rose to $38,347 thousand in the quarter while cash, cash equivalents…
- 10-Q · August 7, 2025
- Atea reported a narrower Q2 net loss of $37,161 (EPS -$0.44) versus a loss of $40,522 (EPS -$0.48) in the prior-year quarter, driven by lower operating expenses. Liquidity remains strong with $379.7 million in cash,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AVIR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever